EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for empagliflozin; linagliptin; metformin hydrochloride and what is the scope of freedom to operate?

Empagliflozin; linagliptin; metformin hydrochloride is the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in one NDA. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Empagliflozin; linagliptin; metformin hydrochloride has four hundred and one patent family members in forty-five countries.

One supplier is listed for this compound.

Summary for EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

International Patents:	401
US Patents:	16
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	18
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE
DailyMed Link:	EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Constraining patent/regulatory exclusivity:

9,155,705

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Humanis Saglk Anonim Sirketi	PHASE1
Medanta, The Medicity, India	N/A
Bahria University	PHASE4

See all EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE clinical trials

Pharmacology for EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors Sodium-Glucose Transporter 2 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

A10BA	Biguanides
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

A10BK	Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIJARDY XR	Extended-release Tablets	empagliflozin; linagliptin; metformin hydrochloride	5 mg/2.5 mg/1 g, 10 mg/5 mg/1 g, 12.5 mg/5 mg/1 g, 25 mg/5 mg/1 g	212614	1	2020-05-26

US Patents and Regulatory Information for EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-003	Jan 27, 2020		RX	Yes	No	8,883,805*PED				Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-002	Jan 27, 2020		RX	Yes	No	10,596,120		Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020		RX	Yes	Yes	8,551,957*PED				Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-003	Jan 27, 2020		RX	Yes	No	12,115,179*PED				Y

Expired US Patents for EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020	6,488,962
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-002	Jan 27, 2020	8,119,648
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020	8,178,541
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020	6,488,962

International Patents for EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
China	109893534	依帕列净的治疗用途 (Therapeutic uses of empagliflozin)
Tunisia	2010000073	COMPOSITON PHARMACEUTIQUE CONTENANT UN DERIVE DE BENZENE SUBSTITUE PAR GLUCOPYRANOSYLE
Poland	2287164
European Patent Office	2360164	Derives de benzene substitues par glucopyranosyle, medicaments renfermant ces composes, leur utilisation et leur procede de fabrication (Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof)

Supplementary Protection Certificates for EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2187879	LUC00017	Luxembourg		PRODUCT NAME: GLYXAMBI- EMPAGLIFLOZINE/LINAGLIPTINE; AUTHORISATION NUMBER AND DATE: EU/1/16/1146 20161115
1730131	C01730131/02	Switzerland		PRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015
2187879	SPC/GB17/031	United Kingdom		PRODUCT NAME: 1-CHLORO-4-(SS-D-GLUCOPYRANOS-1-YL)-2-(4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL)-BENZENE (I.E. EMPAGLIFLOZIN) IN COMBINATION WITH 1-((4 METHYL-QUINAZOLIN-2-YL)METHYL)-3-METHYL-7-(2-BUTYN-1-YL)-8-(3-(R)-AMINO-PIPERIDIN-1-YL)-XANTHINE (I.E. LINAGLIPTIN) OR A P; REGISTERED: UK PLGB 14598/0191 (GB) 20161115; UK EU/1/16/1146/014(NI) 20161115; UK EU/1/16/1146/015(NI) 20161115; UK EU/1/16/1146/016(NI) 20161115; UK EU/1/16/1146/017(NI) 20161115; UK EU/1/16/1146/018(NI) 20161115; UK EU/1/16/1146/007(NI) 20161115; UK EU/1/16/1146/001(NI) 20161115; UK EU/1/16/1146/013(NI) 20161115; UK EU/1/16/1146/002(NI) 20161115; UK EU/1/16/1146/003(NI) 20161115; UK EU/1/16/1146/004(NI) 20161115; UK...
1730131	C20140033 00134	Estonia		PRODUCT NAME: EMPAGLIFLOSIIN;REG NO/DATE: EU/1/14/930 27.05.2014

Market Dynamics and Financial Trajectory of EMPAGLIFLOZIN, LINAGLIPTIN, and METFORMIN HYDROCHLORIDE

Last updated: January 17, 2026

Executive Summary

This analysis examines the market dynamics and financial trajectories for three key antidiabetic drugs: Empagliflozin, Linagliptin, and Metformin Hydrochloride. These medications are central to the management of Type 2 Diabetes Mellitus (T2DM), which remains a significant global health concern with rising prevalence. The focus includes current market size, growth drivers, competitive landscape, regulatory trends, and revenue forecasts through 2030.

Market Overview and Key Drivers

Parameter	Empagliflozin	Linagliptin	Metformin Hydrochloride
Therapeutic Class	SGLT2 inhibitor	DPP-4 inhibitor	Biguanide
Approved Since	2014 (Jardiance)	2011 (Tradjenta)	1957 (original), 1995 (international approval)
Global Market Size (2022)	~$5.2 billion	~$4.1 billion	~$3.7 billion
Mechanism	Inhibits renal glucose reabsorption	Enhances incretin levels	Decreases hepatic glucose production

Key Market Drivers:

• Growing T2DM Prevalence: Estimated to affect 537 million adults globally in 2021, projected to reach 700 million by 2045 (1).
• Shift Toward Novel Mechanisms: Increased adoption of SGLT2 inhibitors and DPP-4 inhibitors due to improved safety and efficacy profiles.
• Regulatory Approvals & Label Expansions: New indications, including heart failure and chronic kidney disease (CKD).
• Brand and Patent Expirations: Easing of market entry for generics, especially for Metformin.
• Emerging biosimilars and generics: Impacting pricing and access dynamics.

Market Dynamics & Competitive Landscape

Empagliflozin

Market Positioning:
Empagliflozin, marketed as Jardiance, is among the leading SGLT2 inhibitors backed by strong cardiovascular (CV) and renal benefit data, notably the EMPA-REG OUTCOME trial (2).

Key Competitors:

• Dapagliflozin (Farxiga)
• Canagliflozin (Invokana)
• Ertugliflozin (Steglatro)

Market Share Trends:

• Empagliflozin holds approximately 25-30% of the SGLT2 class share globally.
• Growing adoption due to CV and CKD benefits.
• Upcoming biosimilars and generic versions could influence pricing strategies.

Growth Forecast (2023-2030):

• CAGR predicted at 12%
• Revenue could reach ~$10 billion globally by 2030 with key expansion in Asia-Pacific and Latin America.

Linagliptin

Market Positioning:
As a once-daily, non-renally cleared DPP-4 inhibitor (Tradjenta), Linagliptin is favored for patients with renal impairment.

Key Competitors:

• Sitagliptin (Januvia)
• Saxagliptin (Onglyza)
• Alogliptin (Nesina)

Market Share Trends:

• Linagliptin's unique non-renal clearance confers advantage in polycomorbid populations.
• Estimated global sales reaching ~$4 billion in 2022.

Growth Forecast:

• CAGR of roughly 8-10% through 2030
• Expansion driven by label extensions into combination therapies and broader indications.

Metformin Hydrochloride

Market Positioning:
As the first-line oral therapy for T2DM, Metformin remains the most prescribed antidiabetic agent.

Market Dynamics:

• Market saturation in developed regions.
• Growing generic availability dramatically reduces average pricing.

Impact Factors:

• Patent expirations for branded formulations, enhancing access but potentially compressing margins.
• Increasing off-label use and combination drug formulations extending shelf-life.

Growth Projections:

• Slow but steady growth, potentially reaching ~$4 billion globally by 2030 with emerging markets contributing significantly.

Regulatory and Policy Trends

Policy Area	Implication for Drugs	Examples
Pricing & Reimbursement	Pressure on pricing, rise of biosimilar/generic competition	US Inflation Reduction Act (2022)
Indications Expansion	Additional approvals for CV and CKD benefits	FDA approvals in 2021 for CV outcomes
Patent Law & Biosimilar Entry	Accelerated market access for generics/biosimilars	EMA and FDA pathways
Environmental & Safety Regulations	Impact on manufacturing and disposal policies	EU Green Deal initiatives

Revenue Projections & Financial Trajectory

Empagliflozin

Year	Estimated Revenue (USD)	Growth Rate	Notes
2022	~$5.2 billion	—	Current market leader favoring CV/renal benefits
2025	~$7.0 billion	10-12% CAGR	Market expansion in Asia & new indications
2030	~$10.0 billion		Dominance amplified by emerging markets

Linagliptin

Year	Estimated Revenue (USD)	Growth Rate	Notes
2022	~$4.1 billion	—	Non-renal clearance benefit sustains market share
2025	~$5.0 billion	8-10% CAGR	Increasing combination formulations
2030	~$6.5 billion		Broader indication approvals bolster sales

Metformin Hydrochloride

Year	Estimated Revenue (USD)	Growth Rate	Notes
2022	~$3.7 billion	—	Market saturation in developed markets
2025	~$4.0 billion	1-3% CAGR	Growth driven primarily by emerging markets
2030	~$4.2 billion		Impact of generic competition stabilized

Deep Dive Comparison

Parameter	Empagliflozin	Linagliptin	Metformin
Mechanism	SGLT2 inhibition	DPP-4 inhibition	Biguanide, reduces hepatic glucose
FDA Approved Indications	T2DM, CV, CKD	T2DM, renal impairment	T2DM (initially), off-label for PCOS
Patent Status	Patent expiry in key markets (2026-2028)	Patent expiry varies; still under exclusivity in some regions	Broad generic availability
Pricing (USD per treating year)	~$500–$700	~$400–$600	<$50 (generic)
Adverse Profile	Genital infections, dehydration	Nasopharyngitis, pancreatitis risk	Generally well-tolerated, lactic acidosis rare

Market Challenges and Opportunities

Challenges

• Generic Entry: Pressure on pricing as patents expire.
• Safety Concerns: Rare risks such as ketoacidosis with SGLT2 inhibitors or pancreatitis with DPP-4 inhibitors.
• Regulatory Hurdles: Approval for additional indications varies across regions.
• Market Saturation: Particularly for Metformin in mature markets.

Opportunities

• Combination Therapies: Fixed-dose combinations (FDCs) enhance adherence and market share.
• Expanding Indications: CV and CKD benefits increase drug value proposition.
• Emerging Markets: Rapid T2DM growth in Asia-Pacific and Africa opens significant sales channels.
• Biosimilar & Generic Competition: Can lower entry barriers for new players.

Key Takeaways

• Empagliflozin is positioned as a leading CV and renal protective agent with a forecast growth driven by expanding indications and market penetration in Asia-Pacific and Latin America.
• Linagliptin capitalizes on its renal clearance advantage, supporting sustained growth amid increasing combination therapies and indications.
• Metformin remains the foundational therapy with stable revenues, but growth opportunities are limited by patent expirations and market saturation in developed regions.
• Regulatory trends, notably approvals for CV and CKD indications and the rise of biosimilars, will influence pricing strategies and market shares.
• Market consolidation, patent expiries, and biosimilar entries are central themes shaping the future revenue trajectory of these agents.

Frequently Asked Questions

1. How will patent expirations impact the revenue of Empagliflozin, Linagliptin, and Metformin?

Patent expirations typically lead to widespread generic availability, significantly reducing prices and revenue. For Empagliflozin, patent cliffs are expected around 2026–2028, which could halve its revenue if biosimilar competition emerges. Linagliptin's patent expiration varies by market but may occur before 2030, while Metformin's original patents expired in the early 2000s, leading to dominance of generics.

2. What strategic moves are pharmaceutical companies making to sustain growth amid biosimilar competition?

Companies are expanding indications to include CV and renal benefits, developing fixed-dose combinations, and entering emerging markets. Investment in pipeline products and patent extensions through new formulations or delivery methods also mitigate biosimilar impacts.

3. Which markets offer the most growth potential for these drugs?

Emerging markets such as China, India, and Africa present substantial growth opportunities due to rising T2DM prevalence. Additionally, expanding indications in North America and Europe, especially for CV and CKD, will sustain revenue streams.

4. How do safety profiles influence market adoption?

Superior safety profiles (e.g., lower hypoglycemia risk for DPP-4 inhibitors, CV/renal benefits for SGLT2 inhibitors) favor adoption. Safety concerns like diabetic ketoacidosis (SGLT2) and pancreatitis (DPP-4) require proactive management and influence prescribing behavior.

5. What role do new regulatory policies play in the future of these drugs?

Policies facilitating fast-track approvals for expanded indications and incentivizing biosimilar development will accelerate market entry and competition, impacting pricing strategies and revenue forecasts. Conversely, stringent safety and environmental regulations could impose manufacturing costs.

References

1. International Diabetes Federation. (2021). IDF Diabetes Atlas, 10th Edition.
2. Zinman et al., “Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes,” New England Journal of Medicine, 2018.